ClinicalTrials.gg
TerminatedNCT04549363Updated Dec 13, 2023Results posted

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

A Phase 3 interventional study of Belantamab mafodotin in Multiple Myeloma, sponsored by GlaxoSmithKline. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Basic science

Why this study was terminated
The study has been terminated for reasons pertaining to feasibility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
37th of 49
16 · median 50
Started
2020
with 5 others
Phase 3
9 of 49
2 open now
Registered
12th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 37th largest by enrollment, is one of 6 that started in 2020, is one of 9 in phase 3, and was the 12th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

This study will be available to any participant who has received or is currently receiving belantamab mafodotin treatment through either a clinical trial, an access program, or a physician prescription. Participants do not need to be on active treatment. The purpose of this study is to gain a more complete understanding of the pathophysiology of the corneal events seen in some participants with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin. A superficial corneal epithelial tissue specimen will be obtained by performing impression cytology (IC) or superficial keratectomy (SK) procedure in participants treated with belantamab mafodotin. The procedure will only be performed in one eye, most affected by the corneal epithelial changes. This specimen will undergo pathologic examination and composition analysis.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Belantamab mafodotin
  • Impression cytology
  • Superficial keratectomy
  • Relapsed/Refractory multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18 years or older (at the time consent is obtained).
  • Capable of providing signed written , which includes compliance with the requirements and restrictions listed on the consent form.
  • Participants with RRMM who have received or are currently receiving treatment with belantamab mafodotin and diagnosed with microcyst-like epithelial changes (MECs) on slit-lamp examination or confocal microscopy, with or without symptoms, in at least one eye.

    a) If participants only had superficial punctate keratopathy with no evidence of MEC's they are not eligible.

  • If undergoing SK procedure, treating provider has determined there is no excessive risk to the participant.

Exclusion criteria

Exclusion Criteria:

  • Any serious and or/unstable medical or psychiatric disorder, or other conditions that could interfere with the participant's safety.
  • Any excess risk of delayed wound healing (For example, diabetes mellitus).
  • Do not meet criteria specified by the study or program through which they would receive belantamab mafodotin.
  • Any participant taking concurrent medication that may affect the cornea (that is. amiodarone, some chloroquines).
  • Any participant with decreased corneal sensation.
  • Eye infections, including infectious keratopathy, stye, blepharitis, and conjunctivitis.
  • An active uveitis including anterior, posterior, or panuveitis in either eye.
  • Permanent legal blindness in the fellow (non-study) eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Participants undergoing IC

    IC will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination and who do not agree to undergo SK.

    Drug: Belantamab mafodotin

  • Experimental
    Participants undergoing SK

    SK will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.

    Drug: Belantamab mafodotin

Interventions

  • Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Abnormality in Composition of Corneal Epithelium After Administration of Belantamab Mafodotin

    Corneal tissue samples were collected to evaluate the composition of microcyst-like epithelium observed in participants treated with belantamab mafodotin.

    Time frame: Up to approximately 23 months

  2. Number of Participants With Abnormality in Pathologic Characteristics After Administration of Belantamab Mafodotin

    Corneal tissue samples were collected to evaluate pathologic characteristics observed in participants treated with belantamab mafodotin.

    Time frame: Up to approximately 23 months

Secondary outcomes

  1. Number of Participants With Imaging Data Showing Histopathologic Findings

    The eye was visualized using a slit-lamp microscope in a procedure room.

    Time frame: Up to approximately 23 months

  2. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 23 months

07

Results

Posted Dec 13, 2023

Participant flow

The study has been terminated for reasons pertaining to feasibility.

Participant flow — Overall Study
MilestoneParticipants Allocated to Undergo Impression Cytology ProcedureParticipants Allocated to Undergo Superficial Keratectomy Procedure
Started63
Icsk population63
Eicsk population42
Completed63
Not completed00

Outcome measures

PrimaryNumber of Participants With Abnormality in Composition of Corneal Epithelium After Administration of Belantamab Mafodotin

Corneal tissue samples were collected to evaluate the composition of microcyst-like epithelium observed in participants treated with belantamab mafodotin.

Time frame:
Up to approximately 23 months
Reported as:
Count of participants · Participants
Number of Participants With Abnormality in Composition of Corneal Epithelium After Administration of Belantamab Mafodotin
ParticipantsParticipants Allocated to Undergo Impression Cytology ProcedureParticipants Allocated to Undergo Superficial Keratectomy Procedure
Number of Participants With Abnormality in Composition of Corneal Epithelium After Administration of Belantamab Mafodotin42
PrimaryNumber of Participants With Abnormality in Pathologic Characteristics After Administration of Belantamab Mafodotin

Corneal tissue samples were collected to evaluate pathologic characteristics observed in participants treated with belantamab mafodotin.

Time frame:
Up to approximately 23 months
Reported as:
Count of participants · Participants
Number of Participants With Abnormality in Pathologic Characteristics After Administration of Belantamab Mafodotin
ParticipantsParticipants Allocated to Undergo Impression Cytology ProcedureParticipants Allocated to Undergo Superficial Keratectomy Procedure
Number of Participants With Abnormality in Pathologic Characteristics After Administration of Belantamab Mafodotin42
SecondaryNumber of Participants With Imaging Data Showing Histopathologic Findings

The eye was visualized using a slit-lamp microscope in a procedure room.

Time frame:
Up to approximately 23 months
Reported as:
Count of participants · Participants
Number of Participants With Imaging Data Showing Histopathologic Findings
ParticipantsParticipants Allocated to Undergo Impression Cytology ProcedureParticipants Allocated to Undergo Superficial Keratectomy Procedure
Number of Participants With Imaging Data Showing Histopathologic Findings23
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 23 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsParticipants Allocated to Undergo Impression Cytology ProcedureParticipants Allocated to Undergo Superficial Keratectomy Procedure
Number of Participants With Adverse Events (AEs)00

Adverse events

Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected up to approximately 23 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Allocated to Undergo Impression Cytology Procedure0/6 (0%)0/6 (0%)0/6 (0%)
Participants Allocated to Undergo Superficial Keratectomy Procedure0/3 (0%)0/3 (0%)0/3 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants Allocated to Undergo Impression Cytology ProcedureParticipants Allocated to Undergo Superficial Keratectomy ProcedureTotal
Mean68.5 ± 9.0571.3 ± 8.5069.4 ± 8.44
Sex: Female, Male
Sex: Female, Male(Participants)Participants Allocated to Undergo Impression Cytology ProcedureParticipants Allocated to Undergo Superficial Keratectomy ProcedureTotal
Female336
Male303
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Allocated to Undergo Impression Cytology ProcedureParticipants Allocated to Undergo Superficial Keratectomy ProcedureTotal
Not Hispanic or Latino639
08

Study locations

6 sites
  • GSK Investigational Site
    San Francisco, California 94143, United States
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Westwood, Kansas 66205, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27517, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Nov 2022, 23 months.

Results were first posted in Dec 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Sep 16, 2020
StartActual
Dec 21, 2020
Primary completionActual
Nov 21, 2022
CompletionActual
Nov 21, 2022
Results first posted
Dec 13, 2023
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04549363
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Dec 21, 2020
Primary completion
Nov 21, 2022
Completion
Nov 21, 2022
Results posted
Dec 13, 2023
Last update
Dec 13, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion